In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Sex-specific management in patients with acute myocardial infarction and cardiogenic shock

Session ACVC Essentials 4 You - ePublications

Speaker Maria Rubini Gimenez

Event : ACVC Essentials 4 You 2020

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Cardiac Care – Cardiogenic Shock
  • Session type : ePublication

Authors : M Rubini Gimenez (Leipzig,DE), U Zeymer (Ludwigshafen,DE), S Desch (Leipzig,DE), S De Waha-Thiele (Luebeck,DE), J Poess (Luebeck,DE), G Fuernau (Luebeck,DE), J Stepinska (Warsaw,PL), K Huber (Vienna,AT), H Thiele (Leipzig,DE)

Authors:
M Rubini Gimenez1 , U Zeymer2 , S Desch1 , S De Waha-Thiele3 , J Poess3 , G Fuernau3 , J Stepinska4 , K Huber5 , H Thiele1 , 1Heart Center of Leipzig - Leipzig - Germany , 2Klinikum Ludwigshafen - Ludwigshafen - Germany , 3University Heart Center - Luebeck - Germany , 4Institute of Cardiology - Warsaw - Poland , 5Medical University of Vienna - Vienna - Austria ,

On behalf: CULPRIT-SHOCK Trial

Citation:

Background: Women are more likely to suffer and die from cardiogenic shock (CS) as the most severe complication of acute myocardial infarction (AMI). Data concerning optimal management for women with CS are scarce.

Aim of this study was therefore to better define characteristics of women suffering CS and to investigate the influence of sex on different treatment strategies including coronary revascularization.

Methods: In the CULPRIT-SHOCK trial, patients with CS complicating AMI and multivessel coronary artery disease were randomly assigned to one of the following coronary revascularization strategies: either percutaneous coronary intervention (PCI) of the culprit-lesion-only or immediate multivessel PCI. Primary endpoint was a composite of death from any cause or severe renal failure leading to renal replacement therapy within 30 days after randomization. We investigated sex-specific differences in general and according to the revascularization strategies.

Results: Among all 686 randomized patients included in the analysis 24% were female. Women were older, had more often diabetes mellitus and known renal insufficiency, whereas they had less often a history of previous AMI and smoking. After 30 days, the primary clinical endpoint was not significantly different between groups (56% women versus 49% men, OR 1.29; 95% CI 0.91 -1.84; p=0.15). There was no interaction between sex and coronary revascularization strategy regarding mortality  and renal failure (pinteraction=0.11), the primary endpoint occurred in 56% of women treated by the culprit-lesion-only strategy vs. 42% men, whereas 55% of women and of men in the multivessel PCI group experienced the primary endpoint.

Conclusions: Although women presented with a different risk profile, mortality and renal replacement after 30 days were similar to men. Sex did not influence mortality and renal failure according to the different coronary revascularization strategies. These data suggest that women and men presenting with CS complicating AMI and multivessel coronary artery disease should be treated equally.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are